InVivo Therapeutics Announces Postponement of Annual Meeting
July 12 2019 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today
announced that it has postponed its 2019 annual meeting of
stockholders. The annual meeting, which was originally scheduled
for June 11, 2019, had been adjourned until July 11, 2019 at 8:00
am Eastern Time. Less than a majority of the shares of the
Company’s outstanding common stock entitled to vote at the meeting
were present in person or by proxy on July 11, 2019, and the
Company therefore determined that a quorum did not exist. The
Company anticipates publicly announcing a new record date and the
new date, time and location of the annual meeting later in
2019.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. These statements
can be identified by words such as “believe,” “anticipate,”
“intend,” “estimate,” “will,” “may,” “should,” “expect” and similar
expressions, and include statements regarding the expectations
related to the announcement of a new annual meeting record date and
new date, time and location of the meeting. Any forward-looking
statements contained herein are based on current expectations and
are subject to a number of risks and uncertainties. Factors that
could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to successfully
open additional clinical sites for enrollment and to enroll
additional patients; the timing of the Institutional Review Board
process; the Company’s ability to obtain FDA approval to
commercialize its products; the Company’s ability to develop,
market and sell products based on its technology; the expected
benefits and efficacy of the Company’s products and technology in
connection with spinal cord injuries; the availability of
substantial additional funding for the Company to continue its
operations and to conduct research and development, clinical
studies and future product commercialization; and other risks
associated with the Company’s business, research, product
development, regulatory approval, marketing and distribution plans
and strategies identified and described in more detail in the
Company’s Quarterly Report on Form 10-Q for the quarter ended March
31, 2019, and its other filings with the SEC, including the
Company’s Form 10-K, Form 10-Qs and current reports on Form 8-K.
The Company does not undertake to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190712005074/en/
IR CONTACT: Bret Shapiro, Managing Partner CORE IR Phone:
(516) 222-2560 brets@coreir.com
MEDIA CONTACT: Jules Abraham CORE IR Phone: (917)
885-7378 julesa@coreir.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2023 to Apr 2024